Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2016
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J06BC04
|
| gptkbp:brand |
gptkb:Anthim
|
| gptkbp:CASNumber |
gptkb:914257-21-9
|
| gptkbp:developedBy |
gptkb:Elusys_Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
obiltoxaximab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:IgG1_kappa
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:target |
gptkb:protective_antigen_of_Bacillus_anthracis
|
| gptkbp:UNII |
6B9Y2V4F3F
|
| gptkbp:usedFor |
treatment of inhalational anthrax
|
| gptkbp:bfsParent |
gptkb:ABthrax
|
| gptkbp:bfsLayer |
7
|